AdvicenneFRA:3MM -9.18%28 Days Payable is 80.73 as of Dec. 2025, which is 14% below its 10-year median of 94.04. GuruFocus rates FRA:3MM with a GF Score™ of 28/100 and a GF Value™ of €1.99 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 708 Biotechnology companies, Advicenne ranks worse than 56.07% on this metric.
Advicenne's average Accounts Payable for the
six
months ended in Dec. 2025 was €1.47 Mil. Advicenne's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €3.31 Mil.
Hence, Advicenne's Days Payable for the
six
months ended in Dec. 2025 was 80.73.
The historical rank and industry rank for Advicenne's Days Payable or its related term are showing as below:
FRA:3MM'
s Days Payable Range Over the Past 10 Years
Min: 59.24 Med: 94.04 Max: 1718.1
Current: 87.16
During the past 12 years, Advicenne's highest Days Payable was 1718.10. The lowest was 59.24. And the median was 94.04.
FRA:3MM's Days Payable is ranked worse than 56.07% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:3MM: 87.16
Advicenne's Days Payable
declined
from Dec. 2024 (96.38) to Dec. 2025 (80.73).
It may suggest that Advicenneaccelerated paying its suppliers.
Advicenne Days Payable Related Terms
Advicenne Days Payable Historical Data
* Premium members only.
The historical data trend for Advicenne's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3MM vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Advicenne's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advicenne Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advicenne's Days Payable distribution charts can be found below:
* The bar in red indicates where Advicenne's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Advicenne's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advicenne (FRA:3MM) has a Days Payable of 80.73 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Advicenne and its competitors. This is 14% below median its historical median of 94.04. Over the past decade, Advicenne's Days Payable has ranged from 59.24 to 1,718.10. According to the industry distribution chart, Advicenne ranks #397 out of 708 companies in the Biotechnology industry, placing it in the top 56.1%.
Is Advicenne's Days Payable too high?
Advicenne's current Days Payable of 80.73 is 14% below median its 10-year median of 94.04. Over the past 10 years, this metric has ranged from a low of 59.24 to a high of 1,718.10. The Biotechnology industry median Days Payable is 113.56. Advicenne's value of 80.73 is 28.9% below this industry median. Based on the distribution chart, Advicenne ranks #397 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Advicenne has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Advicenne's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Advicenne ranks #397 out of 708 companies for Days Payable. This places Advicenne in the lower half of its industry. The industry median Days Payable is 113.56. Advicenne's value of 80.73 is 28.9% below this benchmark. Historically, Advicenne's own Days Payable has ranged from 59.24 to 1,718.10 over the past decade. While the company's 10-year median is 94.04 vs. the industry median of 113.56, Advicenne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advicenne's current Days Payable of 80.73 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Advicenne and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advicenne's current Days Payable is 80.73, which is 14% below median its own 10-year median of 94.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advicenne stock overvalued right now?
Based on GuruFocus' analysis, Advicenne (FRA:3MM) is currently considered Possible Value Trap. The stock's GF Value™ is €1.99, compared to a current price of €1.00 — trading 49.8% below its estimated fair value. The current Days Payable is 80.73, which is 14% below median its 10-year median of 94.04 and 28.9% below the Biotechnology industry median of 113.56. Advicenne's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Advicenne (FRA:3MM), the current Days Payable is 80.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advicenne (FRA:3MM) Overvalued in 2026?
Based on GuruFocus' analysis, Advicenne stock appears to be undervalued.
The current stock price of €1.00 is trading 49.8% below its estimated GF Value™ of €1.99.
GuruFocus considers Advicenne to be Possible Value Trap.
Key valuation signals for FRA:3MM:
Days Payable: 80.73 (14% below median its 10-year median of 94.04)
GF Value™: €1.99 vs. price of €1.00 (49.8% below fair value)
Industry Position: 28.9% below the Biotechnology median (#397 of 708)
No single metric tells the full story. See the FRA:3MM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
28GF Score
Get the complete analysis for FRA:3MM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3MM has been successfully added to your 
